Immunoexpression of Ki-67, MCM2, and MCM3 in Ameloblastoma and Ameloblastic Carcinoma and Their Correlations with Clinical and Histopathological Patterns
Ramón Gil Carreón-Burciaga(Universidad de la República de Uruguay), Ronell Bologna‐Molina(Universidad de la República de Uruguay), Nelly Molina‐Frechero(Universidad Autónoma Metropolitana), Rogelio González‐González(Universidad de la República de Uruguay)
Cited by 45
Related Papers
Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors
|Medicina oral, patología oral y cirugía bucal|2012|253
Extranodal NK/T cell lymphoma, nasal type: An updated overview
|Critical Reviews in Oncology/Hematology|2021|111
Syndecan-1 (CD138) and Ki-67 expression in different subtypes of ameloblastomas
|Oral Oncology|2008|83
Comparative expression of syndecan‐1 and Ki‐67 in peripheral and desmoplastic ameloblastomas and ameloblastic carcinoma
|Pathology International|2009|62
Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review
|World Journal of Clinical Oncology|2019|58